Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Cushing Syndrome 1Adrenal Cortex Neoplasms 1Acth-Independent Macronodular Adrenal Hyperplasia 1ACTH Syndrome, Ectopic 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Osilodrostat × Clear all
NCT02468193 2020-05-06

Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome

Novartis

Phase 2 Completed
9 enrolled 22 charts

Acth-Independent Macronodular Adrenal Hyperplasia, ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Cushing Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡